Steven R. Schneider
Publications by Year
Research Areas
Corporate Taxation and Avoidance, Taxation and Legal Issues, Asymmetric Synthesis and Catalysis, Neurotransmitter Receptor Influence on Behavior, Cannabis and Cannabinoid Research
Most-Cited Works
- → Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics(2003)94 cited
- → Discovery of 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a Novel, Bicyclic Lactam-Based Cannabinoid-1 Receptor Antagonist for the Treatment of Obesity(2009)45 cited
- → Design of a Potent CB1Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents(2012)39 cited
- → 1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes(2011)20 cited
- → Potent and selective, sulfamide-based human β3-adrenergic receptor agonists(2004)16 cited
- → Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles(2009)11 cited
- → An improved synthesis of 5,6,7,8‐tetrahydro‐1,7‐naphthyridine ‐ a conformationally‐restricted analog of 2‐(3‐pyridyl)ethylamine(2001)4 cited
- → The stereoselective syntheses of 1-aryl-1,6-dideoxyinositol derivatives(2011)2 cited
- Structuring (and Drafting) Joint Venture Agreements (PowerPoint)(2016)
- → Potent and Selective, Sulfamide‐Based Human β3‐Adrenergic Receptor Agonists.(2004)